Sentences with phrase «of treatment therapies»

A variety of treatment therapies are provided, including reflexology.

A variety of treatment therapies are provided, including aromatherapy and Ayurvedic.

A variety of treatment therapies are provided, including aromatherapy and reflexology.

Each type of cancer requires individual care and may include a combination of treatment therapies such as surgery, chemotherapy, radiation, cryosurgery (freezing), hyperthermia (heating) or immunotherapy.

Not exact matches

Furthermore, an early - stage study pumping up the dose of its hemophilia A treatment — which aims to be a one - time therapy for the rare blood clotting - related disease — appeared to hit its targets without serious side effects.

Spark Therapeutics» stock soared 20 % in Wednesday trading on the heels of its second quarter 2017 earnings report and some (very) early data on the gene therapy - focused firm's treatment for the blood disorder hemophilia A.

But the initiative comes with another huge financial prize for firms that successfully win FDA approval for these niche therapies: a priority review voucher that can be used to slash the regulatory period for a different experimental specialty treatment being developed by a drug maker or, more often, sold for potentially hundreds of millions of dollars to another pharma company.

In an interview with Cramer, Doyle told CNBC that the first part of the company's growth plan will stem from three sources: international expansion, domestic expansion and its patients, as more and more shift to using Novocure's therapy as their primary treatment.

A panel of experts which advises the Food and Drug Administration (FDA) has unanimously voted to recommend approval of a pioneering cancer therapy from Novartis, setting up a likely approval for the first - of - its - kind treatment.

The facility used straight jackets, electroshock therapy, and lobotomies as methods of treatment for mental illnesses.

The treatment, named Kymriah, was hailed by doctors and the life sciences community as a major advance in medicine and a boon to children and young adults with a certain form of leukemia (the group for whom the gene therapy is approved).

RecoverX makes a connected device that can deliver hot or cold therapy treatments without the use of ice or water.

As a result, phage therapy is now used only for the sickest patients, as a treatment of last resort.

Psychologists and other medical professionals are using VR to heighten traditional therapy methods and find effective solutions for treatments of PTSD, anxiety and social disorders.

As I've chronicled extensively, Exondys is an extremely controversial treatment, and the FDA's decision to approve the therapy over the objections of the agency's own scientific staff stunned many observers last year, raising questions about whether or not the FDA had succumbed to a well - orchestrated and heart - wrenching PR campaign by patients and advocates.

Insurers like Anthem have refused to cover the exorbitantly pricey treatment (around $ 300,000) since the drug's label admits that Exondys hasn't proved its efficacy, making the therapy a roll of the dice for payers and patients alike.

Another recently approved one - time therapy, Novartis» Kymriah for a form of leukemia, also has an outcomes - based pledge: If the treatment isn't working after a month, Novartis doesn't get paid.

The treatment was approved for the devastating rare disease Duchenne muscular dystrophy but created major divisions within the FDA because it simply hadn't demonstrated a whole lot of efficacy, meaning the pricey therapy is essentially being subjected to a real - world clinical test.

The treatment is delivered just once, a facet of gene therapy that poses unique pricing questions in an industry fueled by steady payments for chronic therapies.

Luxturna is the first of a crop of treatments that target diseases caused by mutations in specific genes, and thus is referred to by many as the first gene therapy in the U.S.

But for all of the attention paid to its cancer drug pipeline, Bristol just scored a breakthrough therapy designation from the Food and Drug Administration for a treatment that targets hepatitis C.

The treatment is a type of so - called CAR T - cell therapy — taking a patient's own immune cells, called T cells, genetically manipulating them to attack specific proteins on cancer, and infusing them back into the patient.

Just this year, over 50 U.S. genetics and gene therapy startups raised at least $ 1 million to support genetics - based treatments, including speeding trails, improving accuracy of tests, and providing better platforms.

«Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower healthcare costs and increase access to important therapies,» said FDA Commissioner Scott Gottlieb in a statement.

An analysis published Sep. 16 in the journal Nature noted that insecticide - treated bed nets, insecticides sprayed on indoor surfaces, and prompt treatment with combination drug therapy collectively helped reduce the spread of malaria throughout a large swath of sub-Saharan Africa.

Gilead subsidiary Kite Pharma (which the biotech giant scooped up ahead of the FDA's approval for Yescarta, a treatment that reengineers patients» immune cells to fight cancer) will have access to Sangamo's platform technology, which could be used to create various types of cancer cell therapies.

About Nohla Therapeutics Nohla Therapeutics is a leading developer of off - the shelf cell therapies for the treatment of cancer and other critical diseases.

And there have been developments in cellular therapies to treat cancer, with two treatments aiming for approval by the end of 2017.

On Wednesday, the U.S. Food and Drug Administration approved Novartis» Kymriah, the first drug for a new kind of cancer treatment called CAR - T cell therapy.

CAR - T cell therapy is a form of immunotherapy, a rapidly developing cancer treatment that uses patients» own immune cells to attack tumors.

«The heart of the conversation we had with everybody is how you translate this very exciting but young science into treatments, into therapies.»

«Today's approval marks another first in the field of gene therapy — both in how the therapy works and in expanding the use of gene therapy beyond the treatment of cancer to the treatment of vision loss — and this milestone reinforces the potential of this breakthrough approach in treating a wide - range of challenging diseases,» FDA Commissioner Scott Gottlieb said in a statement.

Bellicum is among the flurry of biotechs investing heavily into cell therapies such as experimental chimeric antigen receptor T - cell (CAR - T) treatments for cancer (this is the next - gen treatment that involves reprogramming immune cells to become cancer killers and has shown promise in blood cancers, which Bellicum specializes in).

Swiss pharmaceutical giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

Its Sandoz unit was the first to win U.S. approval of a «biosimilar» drug — a treatment that's the cheaper generic equivalent of some of the world's most expensive therapies.

And a third, different kind of gene therapy from Spark Therapeutics — to treat a rare inherited form of blindness — is likely to be approved by the end of 2017, too, making this year a landmark for treatments that manipulate the body's own biological mechanisms in novel new ways to fight deadly diseases.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

«Precision medicine is already positively affecting providers (for example, by reducing ED visits by 30 % through application of molecular profiling treatment strategy); payers ($ 25 billion expected annual spending on genetic tests by 2021, and 45 % of FDA approvals were geared toward targeted therapies in 2013); and pharma (the pharmacogenomics market is expected to be $ 7.5 billion by 2017).»

Samsung Bioepis, which has a pipeline of these kinds of copycat treatments for a number of flagship therapies, specifically cited the price - cutting potential of biosimilars.

Since Marathon won an approval to treat a condition that afflicts fewer than 200,000 Americans per year and has a dearth of treatment options (rather than trying to become an also - ran in the saturated steroid therapy field), it has carte blanche over the drug's pricing.

He's now the executive chairman of Rubius Therapeutics, a biotech firm that's also working with cell therapy to develop treatments like Kymriah that don't have to be as personalized.

But Samsung Bioepis and partner Merck are hoping to claw away some of that market share with a new rival therapy — one that could come at a significant discount to the pricey arthritis and psoriasis treatment, which is J&J's best - selling product by far.

«Based on the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»

Retrophin is a publicly - held biopharmaceutical company focused on the development of therapies for the treatment of serious, catastrophic, or rare diseases.

Accelerator Life Science Partners launched a spinoff company to develop an investigational migraine treatment into a therapy for a variety of seizure disorders and landed...

This active IND enables Aura to begin initial clinical testing of AU - 011, a unique targeted therapy that could transform the primary treatment of patients with OM, a rare and life - threatening disease.

Phoundry enhances Intarcia's internal efforts to build upon the differentiated clinical success of its Phase 3 investigational therapy, ITCA 650, the first injection - free GLP - 1 therapy with the potential to deliver up to a full year of treatment from a single placement.

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

On April 23rd they announced receipt of the FDA's RMAT (Regenerative Medicine Advanced Therapy) designation for ABO - 102 for the treatment of Sanfilippo syndrome Type A (MPS IIIA).